Format

Send to

Choose Destination
Arch Pharm Res. 2018 Feb;41(2):219-228. doi: 10.1007/s12272-017-0985-z. Epub 2017 Nov 17.

Comparison of the adjuvanticity of two adjuvant formulations containing de-O-acylated lipooligosaccharide on Japanese encephalitis vaccine in mice.

Author information

1
Department of Bioscience & Biotechnology, Sejong University, 98 Kunja-dong, Kwangjin-gu, Seoul, 05006, Republic of Korea.
2
Department of Bioscience & Biotechnology, Sejong University, 98 Kunja-dong, Kwangjin-gu, Seoul, 05006, Republic of Korea. nature@sejong.ac.kr.
3
Laboratory Science Division, International Vaccine Institute, Seoul, 08826, Republic of Korea.
4
Department of Bioscience & Biotechnology, Sejong University, 98 Kunja-dong, Kwangjin-gu, Seoul, 05006, Republic of Korea. nglee@sejong.ac.kr.

Abstract

Adjuvants are essential vaccine components used to enhance, accelerate, and/or prolong adaptive immunity against specific vaccine antigens. In this study, we compared the adjuvanticity of two adjuvant formulations containing de-O-acylated lipooligosaccharide (dLOS), a toll-like receptor 4 agonist, on the Japanese encephalitis (JE) vaccine in mice. Mice were immunized once or twice at a two-week interval with inactivated JE vaccine in the absence or presence of adjuvant. We found that both the alum- and the liposome-based formulation induced significantly faster and higher serum IgG antibody responses as compared with the non-adjuvanted vaccine after either one or two immunizations. The antibody titers of the mouse immune sera correlated with 50% plaque reduction neutralization test (PRNT50) antibody titers. In addition, the dLOS/liposome formulation was more effective in inducing a Th1-type immune response than the dLOS/alum formulation, as suggested by a strong antigen-specific interferon (IFN)-γ response. Based on these results, we suggest that both alum- and liposome-based adjuvant formulations containing dLOS may be used for the development of JE vaccines with improved immunogenicity.

KEYWORDS:

Adjuvant formulation; De-O-acylated lipooligosaccharide; Japanese encephalitis vaccine

PMID:
29147873
DOI:
10.1007/s12272-017-0985-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center